Hospital.Help

Bethesda/Maryland – A new variant of adoptive cell transfer, which transfers receptors from T cells from the patient’s cancer metastases to defense cells in the laboratory and then administers these to the patient as an infusion, has achieved remissions in a phase 2 study in patients with colorectal carcinomas that have exhausted all other treatment options. The researchers present their treatment with personalized neoantigen-reactive TCR-transduced T cells in Nature…